Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 5/20 | 0.40 |
| ▸ | CA2 | P00918 | 5/20 | 0.40 |
| ▸ | APLNR | P35414 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18741127 | 0.77 | — | — | |
| SCHEMBL11033174 | 0.75 | THRB (0.35) | THRBLMNA | |
| SCHEMBL27549098 | 0.74 | CA2 (0.43) | CA1CA2APLNRTHRBLMNA | |
| Ammonia Solution, Strong SCHEMBL28197240 | 0.73 | THRB (0.33) | THRBLMNA | |
| SCHEMBL21708252 | 0.72 | — | — | |
| SCHEMBL18254245 | 0.68 | APLNR (0.46) | CA1CA2APLNRTHRBLMNA | |
| SCHEMBL18254253 | 0.68 | APLNR (0.46) | CA1CA2APLNRTHRBLMNA | |
| SCHEMBL18254244 | 0.68 | APLNR (0.46) | CA1CA2APLNRTHRBLMNA | |
| SCHEMBL21767033 | 0.67 | APLNR (0.45) | CA1CA2APLNRTHRBLMNA | |
| SCHEMBL21767034 | 0.67 | APLNR (0.45) | CA1CA2APLNRTHRBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3611175-B1 | NAPHTHALOCYANINE COMPOUND, METHOD FOR PRODUCING SAME, AND USE THEREOF | YAMAMOTO CHEMICALS INC (JP) | 2022-02-09 | — | — | EP | disclosed |
| US-11174274-B2 | Naphthalocyanine compound, method for producing same, and use thereof | YAMAMOTO CHEMICALS, INC. (JP) | 2021-11-16 | — | — | US | disclosed |
| US-20210107924-A1 | NAPHTHALOCYANINE COMPOUND, METHOD FOR PRODUCING SAME, AND USE THEREOF | YAMAMOTO CHEMICALS, INC. (JP) | 2021-04-15 | — | — | US | disclosed |
| EP-3611175-A1 | NAPHTHALOCYANINE COMPOUND, METHOD FOR PRODUCING SAME, AND USE THEREOF | Yamamoto Chemicals, Inc. (JP) | 2020-02-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210107924-A1 | NAPHTHALOCYANINE COMPOUND, METHOD FOR PRODUCING SAME, AND USE THEREOF | MRPS9, INTS9, RPL19 | CA1 734/4885CA2 1085/4885APLNR 4176/4885 |
| US-11174274-B2 | Naphthalocyanine compound, method for producing same, and use thereof | MRPS9, INTS9, RPL19 | CA1 734/4885CA2 1085/4885APLNR 4176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.